Navigation Links
Volcano Corporation Prices $100 Million 2.875 Percent Convertible Senior Notes Due 2015
Date:9/14/2010

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC) today announced the pricing of its offering of $100 million aggregate principal amount of 2.875 percent convertible senior notes due September 1, 2015 registered under the Securities Act of 1933, as amended. Prior to June 1, 2015, the notes will be convertible only upon certain circumstances. Upon conversion, holders will receive up to the principal amount of the notes in cash and any excess conversion value in shares of Volcano's common stock. Volcano granted the underwriter of the offering a 13-day option to purchase up to $15 million aggregate principal amount of additional notes. The offering is expected to close on September 20, 2010, subject to customary closing conditions.

The notes will mature on September 1, 2015, unless previously converted in accordance with their terms prior to such date. The notes will be general senior unsecured obligations of Volcano, and interest will be payable semi-annually in cash at a rate of 2.875 percent per annum on March 1 and September 1 of each year, beginning March 1, 2011. The initial conversion rate of 33.7339 shares of common stock per $1,000 principal amount of notes is equivalent to a conversion price of approximately $29.64 per share of common stock, which is 27.5% higher than the closing price of the Company's stock on September 14, 2010.  The conversion rate is subject to adjustment in certain events, such as distributions of dividends and stock splits.

The company estimates that net proceeds from the offering will be approximately $96.1 million, after deducting the underwriter's discounts and estimated transaction expenses associated with the offering and the convertible note hedge transaction and the warrant transaction payable by the company. The company expects to use approximately $8.7 million of the net proceeds from the sale of the notes to pay the cost of the convertible note hedge transaction (after such cost is partially offset by the proceeds that the company expects to receive from the warrant transaction).  The balance of the net proceeds will be used for working capital and for general corporate purposes.  The company may also use a portion of the net proceeds to expand its manufacturing capabilities and/or invest in complementary products, technologies or businesses.

In order to reduce the potential dilution of the company's common stock upon future conversion of the notes, the company has entered into a convertible note hedge transaction with an affiliate of the underwriter (the "option counterparty"). The company has also entered into a warrant transaction with the option counterparty, which could have a dilutive effect on the company's common stock to the extent that the market value per share of the company's common stock, as measured under the warrant transaction, exceeds the strike price of the warrant transaction.  The warrants have an exercise price of $34.88, which is 50% higher than the closing price of the company's stock on September 14, 2010. If the underwriter exercises its overallotment option to purchase additional notes, the company expects to enter into an additional convertible note hedge transaction and an additional warrant transaction.

In connection with establishing its initial hedge position with respect to the convertible note hedge transaction and the warrant transaction, the option counterparty, and/or its affiliates, expects to enter into various over-the-counter derivative transactions with respect to the company's common stock concurrently with and/or shortly after the pricing of the notes.  These activities could have the effect of increasing, or limiting a decline in, the market price of the company's common stock concurrently with and/or shortly after the pricing of the notes.

In addition, the option counterparty and/or its affiliates may modify its hedge position from time to time prior to conversion or maturity of the notes by entering into and unwinding various over-the-counter derivative transactions and/or purchasing and selling shares of the company's common stock and the company's other securities, including the notes and/or other instruments it may wish to use in connection with such hedging activities (and is likely to do so during any observation period related to a conversion of notes).  

J.P. Morgan Securities LLC is the sole manager of the note offering. The notes are being offered and sold under Volcano's shelf registration statement filed with the Securities and Exchange Commission on September 13, 2010, which was effective upon filing.  Before you invest, you should read the prospectus and prospectus supplement to that registration statement and other documents Volcano has filed with the SEC for more complete information about Volcano and this offering. You may get these documents at the SEC web site at www.sec.gov. Printed copies of the preliminary prospectus supplement relating to this offering may also be obtained by requesting copies from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions at 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 866-803-9204.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.

About Volcano Corporation

Volcano Corporation (Nasdaq: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use digital and rotational IVUS imaging catheters, and advanced functionality options, such as VH® IVUS tissue characterization and ChromaFlo®. Volcano also provides Image-Guided Therapy products that combine the imaging capability of IVUS with cardiovascular therapeutic devices. Volcano has Physiology consoles and single-use pressure and flow guide wires. Currently, more than 5,400 Volcano IVUS and Physiology systems are installed worldwide, with approximately half of Volcano's revenues coming from outside the United States. Volcano is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) systems and catheters, Forward-Looking Imaging catheters and Microcatheters. Volcano's wholly-owned subsidiary, Axsun Technologies, develops and manufactures optical monitors, lasers and optical engines used in telecommunications, medical imaging, spectroscopy and other industrial applications. For more information, visit the company's website at www.volcanocorp.com.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including relating to the offering described above, the current market demand for these types of securities, and the securities of Volcano and the negotiations between Volcano and the underwriter due to changes in our stock price, corporate or other market conditions. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Other risks that could impact the offering or Volcano's business are described in detail of Volcano's annual report on Form 10-K for the year ended December 31, 2009, quarterly report on Form 10-Q for the quarter ended June 30, 2010, current report on Form 8-K filed on September 13, 2010, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
2. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
3. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Volcano Corporation Announces Litigation Status
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance
8. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
9. Volcano Announces Installed Base Growth Milestone
10. Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging
11. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):